Takayasu Arteritis
Return to Library
|
Free Takayasu Arteritis Articles |
|
|
|
|
Studies from University of Siena add new findings in the area of takayasu arteritis
2009 MAY 11 - (NewsRx.com) -- "Takayasu arteritis (TA) is a chronic inflammatory disease of large arteries which progressively develop stenosis, occlusion or aneurismal degeneration. Proinflammatory cytokines and, among these, tumor necrosis factor-alpha (TNF-alpha) are increased and play a pathogenetic role in the development of disease," scientists writing in the journal European Review for Medical and Pharmacological Sciences report. "Conventional therapy often fails to determine clinical remission and, in these cases, pathogenetic strategies with anti-TNF-alpha drugs have been proposed. Infliximab is a human-murine chimeric monoclonal antibody that specifically binds to and neutralizes soluble TNF-a. It is an effective treatment for rheumatoid arthritis, spondyloarthritis, Crohn's disease and ulcerative colitis and it has been recently proposed for the treatment of TA in patients refractory to conventional therapy," wrote S. Maffei and colleagues, University of Siena. The researchers concluded: "Here we report the case of a patient affected by Takayasu arteritis unresponsive to conventional therapy who was then treated with infliximab and obtained a clinical remission of the disease." Maffei and colleagues published their study in European Review for Medical and Pharmacological Sciences (Refractory Takayasu arteritis successfully treated with infliximab. European Review for Medical and Pharmacological Sciences, 2009;13(1):63-65). Additional information can be obtained by contacting A.L. Pasqui, University of Siena, Dept. of Clinic Med & Immunology, Policinico Le Scotte, I-53100 Siena, Italy. The publisher of the journal European Review for Medical and Pharmacological Sciences can be contacted at: Verduci Publisher, Via Gregorio VII, Rome, 186-00165, Italy. Keywords: Italy, Siena, Alternative Medicine, Angiology, Biotechnology, Cardiology, Conventional Therapies, Crohn Disease, Cytokines, Drugs, Gastroenterology, Gastrointestinal, Genetics, Infliximab, Monoclonal Antibodies, Necrosis, Pharmaceuticals, Pharmacological Sciences, Stenosis, Takayasu Arteritis, Therapy, Treatment, Vasculitis, University of Siena. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
